INDICATIONS AND USAGE
DRIZALMA SPRINKLE™ (duloxetine) delayed-release capsules are indicated for the treatment of:
  • Major depressive disorder in adults
  • Generalized anxiety disorder in adults and pediatric patients aged 7 to 17 years
  • Diabetic Peripheral Neuropathic Pain (DPNP) in adults
  • Chronic musculoskeletal pain in adults
  • Fibromyalgia (FM) in adults

Drizalma Sprinkle™ is Covered on Most Medicare Part D Plans

91% of lives on the top 10 Medicare Part D plans are offered coverage for Drizalma Sprinkle™1

Drizalma Sprinkle

An alternative formulation for patients who have difficulty swallowing tablets.


The Only Sprinkle Formulation of Delayed‑Release Duloxetine

designed for patients who cannot or will not swallow solid medication forms2




IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies.
Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.


Please see additional Important Safety Information on the side, as well as the full Prescribing Information, including BOXED WARNING.

3 Administration Options for Your Patients2

Open and sprinkle
over applesauce
Swallow whole
Open and administer
via nasogastric tube
No need for crushing; just open, sprinkle, and serve.

DRUG INTERACTIONS

  • Avoid concomitant use with potent CYP1A2 inhibitors
  • Consider dose reduction with concomitant use with CYP2D6 substrates

Please see additional Important Safety Information on the side, as well as the full Prescribing Information, including BOXED WARNING.

See Indication-
Specific Dosing

In addition to helping treat Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), Drizalma Sprinkle™ can be used for pain management to treat Diabetic Peripheral Neuropathic Pain (DPNP), chronic musculoskeletal pain, and Fibromyalgia (FM)2,3

Learn More About Flexible Administration

Drizalma Sprinkle™ can be administered once daily for most approved indications2

Discover Why Your Patients Might Benefit From Drizalma Sprinkle™

Once-daily Drizalma Sprinkle™ delayed-release capsules help mitigate the risks of improper medication manipulation2,4

References: 1. Data on file. Sun Pharmaceutical Industries, Inc., Princeton, NJ. 2. Drizalma Sprinkle™ [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc., 2021. 3. Kamerlink J; Kamerlink Pain Institute. Non-opioid pain treatment. Accessed October 8, 2020. http://web.brrh.com/msl/GrandRounds/2018/GrandRounds_101618-Non-Opioid-Pain-Management/Non-Opioid%20Pain%20Management-BRRH%20Grand%20Rounds%2010-16-2018.pdf. 4. Institute for Safe Medication Practices. Oral dosage forms that should not be crushed. Published November 1, 2018. Accessed October 26, 2020. www.ismp.org/recommendations/do-not-crush.